https://denosumabinhibitor.com..../equivalence-interac
Progressive cost-effectiveness proportion (ICER) was reported as expense in 2017 U.S. dollars per gain in quality-adjusted life years (QALYs). Willingness-to-pay thresholds of $50,000/QALY and $100,000/QALY were used to determine extremely cost-effective and economical therapies. RESULTS Both DRG and SCS supplied an increase in QALYs (4.96 ± 1.54 and 4.58 ± 1.35 QALYs, respectively) and an increase in costs ($153,992 ± $36,651 and $128,269 ± $27,771, respectively) when
Like
Comment
Share
